Skip to content

DBV Technologies DBVT Enterprise value

Enterprise value at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$315.24M+909%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$787.38M+114%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$2.08B+74.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.14B+874%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$6.74B+280%
Alumis Inc. logo
Alumis Inc.ALMS
$2.77B+1,238%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Calculated from DBV Technologies’s reported figures.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's enterprise value?
DBV Technologies (DBVT) reported enterprise value of $939.37M in Q1 2026.
How has DBV Technologies's enterprise value changed year-over-year?
DBV Technologies's enterprise value increased by 600.0% year-over-year, from $134.19M to $939.37M.
What is the long-term trend for DBV Technologies's enterprise value?
Over 5 years (2020 to 2025), DBV Technologies's enterprise value has grown at a 40.6% compound annual growth rate (CAGR), from $105.97M to $581.66M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.